United States, the prevalence of HTLV-II infection among HIV-infected injection drug users may approach or exceed 10% [8, 14] .
Screening for HTLV-I/II infection is not performed in most HIV outpatient clinics. Conflicting reports suggest variable outcomes among dually infected individuals, including delayed progression to AIDS in some reports and accelerated disease progression in others [5, 10, 11, [15] [16] [17] . Interpretation of these study results is limited by incomplete demographic, laboratory, and treatment data and by lack of differentiation of HTLV-I from HTLV-II in many cases. HTLV-I, HTLV-II, and HIV all involve preferential infection of CD4 + T cells, but they have different effects on host immunity and potential to cause clinical disease [18] . In this article, we report the results of our long-term observational study of HIV-HTLV-I and HIV-HTLV-II coinfections in the New Orleans, Louisiana, HIV Outpatient Clinic (HOP), where 13500 individuals have been tested for HTLV-I/II infection since October 1993.
New Orleans has a high rate of HTLV-I and HTLV-II infection among HIV-infected individuals, with a very high rate of HTLV-II infection among injection drug users [14, 19] . Demographic, clinical, and immunologic features of coinfected and HIVmonoinfected patients were compared.
METHODS

Sample.
The HOP at the Medical Center of Louisiana (New Orleans) is currently the largest provider of HIV outpatient treatment in the Gulf South region. Clinical and demographic data for all patients who return for a second clinic visit are abstracted from medical records and entered into the Centers for Disease Control and Prevention-funded Adult Spectrum of Disease (ASD) study database at 6-month intervals.
From March 1993 through September 2002, ∼3600 HIVinfected patients entering care at the clinic were routinely tested for HTLV-I/II using an EIA screening test (Abbott Laboratories) that detects both HTLV-I and HTLV-II. Western blot analysis (Zeptometrix) was then performed to confirm and differentiate HTLV-I infections from HTLV-II infections.
HOP clinic patients who were tested for HTLV-I/II coinfection and who were included in the ASD database were the target population for this study. Each patient with HIV-HTLV-I/II coinfection was then matched by date of clinic entry (within a window period of 1 month) with up to 4 HIV-monoinfected patients. The patients were stratified into 3 groups: HIVmonoinfected patients ( ), HIV-HTLV-I-coinfected pan p 824 tients ( ), and HIV-HTLV-II-coinfected patients ( n p 62 n p ). For examination of the progression to AIDS and death 141 and for determination of the incidence of opportunistic infections (OIs), a second control group matched on the basis of both date of clinic entry and CD4 + T cell count (categorized as !200, 200-500, 1500 cells/mL) was used to prevent potential selection bias in HIV disease staging or differential exposure to secular events for outcomes of interest. This resulted in a HIV-monoinfected control sample of 284 patients.
Demographic and clinical data.
The following demographic information was recorded at the time of clinic entry: age, sex, race/ethnicity, and self-reported history of injection drug use (IDU). The presence of any of following clinical diagnoses or procedures was noted at each visit: any AIDSdefining diagnosis, encephalopathy, myelopathy, neuropathy, thrombocytopenia, lymphoma or leukemia, lymph node biopsy, bronchitis, urinary tract infection, skin infection or other skin condition, liver disease and cirrhosis, asthma, hepatitis C and B, tuberculosis, pneumonia, or any OIs. These clinical parameters were chosen on the basis of previous literature reporting an increased prevalence of these conditions among HTLV-infected individuals [20] [21] [22] . Prescription of antiretroviral treatment or prophylaxis for OIs was also recorded at each visit. Laboratory parameters included complete blood cell counts with differential platelet counts, as well as determination of virus loads (available after 1996) and T cell subsets (total CD4 + and CD8 + cell counts). T cell and virus load subsets were performed in the Charity Hospital (New Orleans, LA) certified laboratory as part of the patients' routine clinic evaluation. HIV loads were determined using the Amplicor HIV Monitor Assay (Roche Diagnostics).
Statistical analysis. Pairwise comparisons were made between HIV-HTLV-I-coinfected patients, HIV-HTLV-IIcoinfected patients, and HIV-monoinfected control subjects with respect to baseline demographic characteristics and clinical parameters using the x 2 test, Fisher's exact test, Mann-Whitney U test, or analysis of variance, as appropriate. Multivariate logistic regression was used to determine factors associated with HTLV coinfection. Bonferroni adjustments were applied to all P values to prevent spurious associations due to multiple comparisons.
Kaplan-Meier curves and Cox proportional hazards models were used to assess differences in time from clinic entry to AIDS and death between coinfected patients and a random sample of HIV-monoinfected control subjects who were matched on the basis of date of clinic entry and CD4 + T cell count. The number of person-months of follow-up was computed for each patient as the interval between clinic entry and the event of interest or censoring. Patients were censored at the last available contact or at loss to follow-up. To reduce confounding, analyses were adjusted for important baseline covariates, including age, race, IDU, and receipt of antiretroviral therapy. Antiretroviral therapy was included as a time-dependent covariate in the final extended Cox regression model.
Friedman's nonparametric test was used to evaluate the differences in mean CD4 + T cell counts over time between coinfected and HIV-monoinfected patients. The incidence of OIs over time was examined with crude generalized estimating equations (GEE) logistic regression models [23] . GEE allows for intrasubject correlation, which is often treated as a nuisance parameter, among repeated measurements involving the same subject over time, accounting for correlation due to repeated observations [24] . Models were also adjusted for important baseline covariates, as mentioned above. Comparisons of OIs over time was also conducted with the random sample of HIVmonoinfected control subjects who were matched by date of clinic entry and CD4 + T cell count. All statistical analyses were conducted using SAS, version 8.0 (SAS Institute). Mean values are shown with SDs.
RESULTS
During the period of March 1993 through September 2002, a total of 3606 patients were tested for HTLV-I/II infection by screening EIA testing, and 288 patients (8.0%) were found to be HTLV seropositive for types I or II. From this group, a total of 209 patients were identified in the ASD database, and Western blot confirmatory testing revealed HTLV-I coinfection in 62 patients, HTLV-II coinfection in 141 patients, and HTLV-I/ HTLV-II coinfection in 6 patients. The 6 patients with triple infection were excluded from analysis. A random sample of 824 patients with HIV monoinfection, who were matched by date of enrollment into clinic care, was chosen as the primary comparison group. A total of 284 HIV-moninfected control subjects, who were matched by date of enrollment and baseline CD4 + T cell count category (i.e., !200, 200-500, and 1500 cells/ mL), were used as the comparison group for time to AIDS progression and death and incidence of OIs.
Baseline characteristics. Over the course of follow-up, we observed an increased prevalence of clinical conditions among HIV-HTLV-I-and HIV-HTLV-II-coinfected patients. Those with HTLV-I coinfection were significantly ( ) more likely than control subjects to receive a diagnosis P ! .05 of myelopathy, thrombocytopenia, bronchitis, or urinary tract infection or to have positive results of serological tests for hepatitis C-even after adjustment for age, race/ethnicity, CD4 + T cell count, and history of IDU (table 3) . After taking into account the same covariates, individuals with HTLV-II coinfection were significantly ( ) more likely than control sub-P ! .05 jects to have a diagnosis of thrombocytopenia, bronchitis, urinary tract infection, liver disease, or pneumonia or to have positive results of serological tests for hepatitis C. There was also a trend ( ) of a greater prevalence of neuropathy P ! .10 among HIV-HTLV-II-coinfected patients than among HIVmonoinfected control subjects.
Progression to AIDS and death and incidence of OIs. In the cohort examined for time to AIDS and death (in which the control sample [ ] was matched for both time of n p 284 clinic entry and CD4 + T cell count), 102 cases of AIDS occurred during 3550 person-months of follow-up, and 153 deaths occurred during 4629 person-months of follow-up. Table 4 shows the adjusted Cox proportional hazards model for time to AIDS diagnosis and death. After adjusting for age, race, sex, history of IDU, and receipt of antiretroviral therapy, there was a trend toward slower progression to AIDS among patients coinfected with HTLV-I and a significantly slower progression among those coinfected with HTLV-II (adjusted hazard ratio [aHR], 0.50; 95% CI, 0.25-0.98). Progression to death was also significantly slower among HIV-HTLV-II-coinfected patients than among HIV-monoinfected control subjects (aHR, 0.57; 95% CI, 0.37-0.89). Figures 1 and 2 present the adjusted survival curves for progression to AIDS and death among HIV-HTLV-II-coinfected patients, compared with those for HIVmonoinfected control subjects.
To further evaluate the difference in CD4 + T cell count between the 2 groups and the role of CD4 + T cell count in progression to AIDS, we compared CD4 + T cell counts over time and CD4 + T cell count-controlled incidence of OIs. During the course of follow-up, HIV-HTLV-coinfected patients (with either type I or II) had, on average, a higher CD4 + T cell count. Differences were statistically significant ( ) for both HIV-P ! .01 HTLV-I-and HIV-HTLV-II-coinfected patients, compared with HIV-monoinfected control subjects. The results of comparisons in OI incidence over time are also presented in table 4. There were no differences in the occurrence of OIs during follow-up between HIV-HTLV-coinfected patients and HIVmonoinfected control subjects.
DISCUSSION
This study summarizes the findings of our long-term observational study of 209 patients with HIV-HTLV-I/II coinfection who receive medical evaluations at the Charity Hospital Medical Center of the Louisiana HIV Outpatient Clinic. The cohort is unique from other studies in that the clinic population consisted of patients with HTLV-I coinfection as well as those with HTLV-II coinfection. When compared with HIV-monoinfected control subjects, we observed several features associated with coinfected individuals. Coinfections were highly associated with older age, a history of IDU, and African American race/ethnicity. Despite having an older age and a history of IDU, coinfected patients were found to have higher CD4 + T cell counts as a whole at baseline and exhibited slower rates of CD4 + T cell count decreases over time. These findings have been corroborated by others and confirm our earlier study of a smaller number of patients [14, 15, 24] .
Our study also revealed differences in disease progression among coinfected patients. The results indicate that coinfection with HIV and HTLV-II was associated with delayed progression to AIDS. A similar trend was observed in HIV-HTLV-Icoinfected patients, but the difference was not statistically significant. The difference in progression to AIDS may be explained primarily by the delayed rate of decrease in the CD4 + T cell count. Despite this potential immunologic benefit (i.e., a delayed rate of decrease in the CD4 + T cell count and a delay in progression to AIDS), several clinical conditions were more common in coinfected individuals, including pulmonary and urinary tract infections, as well as chronic liver disease due to hepatitis C virus (which was likely associated with increased rates of IDU). This suggests the possibility that there are qualitative and quantitative defects in CD4 + T cell function in coinfected individuals. It is recognized that HTLV-I, HTLV-II, and HIV have the potential for tropism for cell populations other than CD4 + T cells, although this is the principal cell type used for all 3 pathogens. On the basis of the potential for the HTLV viruses to induce clonal expansion of both CD4 + and CD8 + cells, we believe that our clinical observations are compatible with the biology of these viruses [18] . The increased incidence of clinical conditions in coinfected patients may therefore be a composite effect of the viral pathogenicity, as well as altered cellular immune function. We were concerned that high rates of IDU in HIV-HTLVcoinfected patients could somehow exert independent effects on clinical conditions and survival outcomes. Although we adjusted for IDU in the multivariable analysis, we performed a separate analysis using a control group of HIV-monoinfected injection drug users and compared this control group with coinfected injection drug users (data not shown). In this analysis, we found results similar to those described above, with a statistically significant increase in peripheral neuropathy among coinfected injection drug users, compared with HIV-monoinfected injection drug users.
We speculated that HIV-HTLV-I/II coinfection would result in an increased frequency of HTLV-I/II-associated clinical conditions, particularly neurologic manifestations. Because our analysis relies entirely on the use of the ASD database, it is possible that underreporting of neurological conditions occurred as a result of inadequate documentation of neurologic evaluations by nonneurologists in an outpatient setting. However, despite this limitation, we were able to demonstrate an increased prevalence of peripheral neuropathy among coinfected individuals, especially among the subset of injection drug users. We are in the process of enrolling HIV-HTLVcoinfected patients into a prospective study to evaluate these neurologic manifestations quantitatively and over time. Although this data is not shown, results of this study clearly suggest that peripheral neuropathy is underdiagnosed in our clinic database.
We acknowledge certain limitations in this study. Perhaps the major limitation is that dates of seroconversion in our patients are unknown. Without conducting an incidence study of HTLV-I/II infection, it is impossible to know the exact time of infection. However, we expect that, on the basis of the older age of the HTLV-infected population and their risk demographics, HTLV infection preceded HIV infection. This is corroborated by several prior studies suggesting that IDU-related exposure to HTLV-I and -II probably occurred in New Orleans during the late 1960s and early 1970s. A published study by Murphy et al. [25] provides additional evidence from blood donors that there has been a 30-year-old epidemic of HTLV-II infection in the United States.
Despite this limitation, we believe that our study is unique in that it includes one of the largest cohorts in the United States and is one of few studies examining progression or survival in which HTLV infection status was known, because HTLV testing is not routinely obtained in most HIV clinics. Participant data were entered into the survival analyses on the basis of the patient's date of entry into the clinic and CD4 + T cell count (which is a proxy measure for the staging of the HIV disease). By matching HIV-monoinfected persons with HIV-HTLVcoinfected persons for these 2 critical values, we believe that we are able to substantially reduce selection bias resulting from exact dates of seroconversion.
A second limitation of our study was that the identification of clinical and social conditions, including peripheral neuropathy and substance use, was predominantly via provider reports in the medical chart, and abstractors did not have standardized definitions data-collection schedules for neuropathy. Furthermore, for some clinical conditions, the small sample size restricted the power of the analysis. Despite these limitations, peripheral neuropathy was significantly associated with HIV-HTLV coinfection. This was unlikely to have been a result of an ascertainment bias, because most clinic providers and data abstracters were aware of the patient's HTLV-I/II serostatus.
The current study does not address possible causes for delayed progression to AIDS among coinfected individuals, although limited published in vitro data offer possible explanations. For example, HTLV-II often infects CD8 + lymphocytes preferentially, and it is possible that HTLV-II-infected CD8 + cells produce C-C chemokines, which may interfere with HIV-1 replication [26] . In an Italian cohort of HIV-1-infected longterm nonprogressors who were coinfected with HTLV-II, it appeared that higher HTLV-II proviral loads correlated with long-term nonprogression to AIDS [24] . Peripheral blood leukocytes obtained from some of these individuals were previously reported to have altered cytokine production, which interfered with HIV-1 infection at multiple levels [27] .
Taken together, these results suggest important considerations in the immunologic staging and treatment of HIV-HTLV-I/II-coinfected individuals. For example, because of significant differences in CD4 + T cell counts, decisions concerning initiation of HAART may need to be modified in coinfected individuals. Optimal antiretroviral therapy for coinfected patients will require additional study, because the antiviral effects of standard triple-drug regimens against HTLV-I/II are unknown [28] . These results also support the contention that HTLV-I/II testing should be more broadly employed among HIV-infected individuals, especially in clinical settings where IDU is a major mode of HIV transmission. Appropriate management should include careful monitoring for development of neurologic complications and an awareness that coinfected individuals may have unique immunologic phenotypes that will ultimately affect treatment decisions and long-term prognosis.
